Akstein E - Search Results

1

Cost-benefit analysis of a national screening programme for cystic fibrosis in an Israeli population.

Ginsberg G, Blau H, Kerem E, Springer C, Kerem BS, Akstein E, Greenberg A, Kolumbos A, Abeliovich D, Gazit E, et al. Ginsberg G, et al. Among authors: akstein e. Health Econ. 1994 Jan-Feb;3(1):5-23. doi: 10.1002/hec.4730030104. Health Econ. 1994. PMID: 8167800

2

A novel mutation in the HEXA gene specific to Tay-Sachs disease carriers of Jewish Iraqi origin.

Karpati M, Peleg L, Gazit E, Akstein E, Goldman B. Karpati M, et al. Among authors: akstein e. Clin Genet. 2000 May;57(5):398-400. doi: 10.1034/j.1399-0004.2000.570512.x. Clin Genet. 2000. PMID: 10852376

3

[Biochemical, molecular and social aspects of carrier screening for Tay-Sachs disease].

Peleg L, Gazit E, Goldman B, Akstein E. Peleg L, et al. Among authors: akstein e. Harefuah. 1995 Dec 1;129(11):475-80. Harefuah. 1995. PMID: 8846957 Review. Hebrew. No abstract available.

4

Prenatal testing for Down syndrome in the Jewish and non-Jewish populations in Israel.

Davidov B, Goldman B, Akstein E, Barkai G, Legum C, Dar H, Romem Y, Amiel A, Cohen H, Bach G, et al. Davidov B, et al. Among authors: akstein e. Isr J Med Sci. 1994 Aug;30(8):629-33. Isr J Med Sci. 1994. PMID: 8045747

5

Tay-Sachs disease and HEXA mutations among Moroccan Jews.

Kaufman M, Grinshpun-Cohen J, Karpati M, Peleg L, Goldman B, Akstein E, Adam A, Navon R. Kaufman M, et al. Among authors: akstein e. Hum Mutat. 1997;10(4):295-300. doi: 10.1002/(SICI)1098-1004(1997)10:4<295::AID-HUMU5>3.0.CO;2-G. Hum Mutat. 1997. PMID: 9338583

6

Congenital adrenal hyperplasia. I. Problems of management associated with late diagnosis. II. Response to gonadotrophin releasing hormone.

Oelsner G, Kraiem Z, Lunenfeld B, Akstein E, Goldman B, Serr DM. Oelsner G, et al. Among authors: akstein e. Monogr Hum Genet. 1978;10:178-80. Monogr Hum Genet. 1978. PMID: 364300 No abstract available.

7

Fluidity difference of membrane lipids in human normal and leukemic lymphocytes as controlled by serum components.

Inbar M, Goldman R, Inbar L, Bursuker I, Goldman B, Akstein E, Segal P, Ipp E, Ben-Bassat I. Inbar M, et al. Among authors: akstein e. Cancer Res. 1977 Sep;37(9):3037-41. Cancer Res. 1977. PMID: 884661

8

Amniocentesis rate and the detection of Down syndrome and other chromosomal anomalies in Israel.

Shohat M, Akstein E, Davidov B, Barkai G, Legum C, David M, Dar H, Romem Y, Amiel A, Cohen H, et al. Shohat M, et al. Among authors: akstein e. Prenat Diagn. 1995 Oct;15(10):967-70. doi: 10.1002/pd.1970151012. Prenat Diagn. 1995. PMID: 8587865

9

Incidence of leukemia and other cancers in Down syndrome subjects in Israel.

Boker LK, Blumstein T, Sadetzki S, Luxenburg O, Litvak I, Akstein E, Modan B. Boker LK, et al. Among authors: akstein e. Int J Cancer. 2001 Sep 1;93(5):741-4. doi: 10.1002/ijc.1383. Int J Cancer. 2001. PMID: 11477589

10

Risk factors for infant mortality in Down's syndrome: a nationwide study.

Sadetzki S, Chetrit A, Akstein E, Luxenburg O, Keinan L, Litvak I, Modan B. Sadetzki S, et al. Among authors: akstein e. Paediatr Perinat Epidemiol. 1999 Oct;13(4):442-51. doi: 10.1046/j.1365-3016.1999.00220.x. Paediatr Perinat Epidemiol. 1999. PMID: 10563363

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Search Page

Filters